Skip Nav Destination
Issues
15 January 2025
-
Cover Image
Cover Image
The cover shows a section of a co-detection-by-indexing (CODEX) image from a patient with recurrent glioblastoma. Distribution of T-cell and myeloid populations shown for PD-L1 (blue), CD31 (blood vessels, cyan), CD45 (immune cells, red), and CD3e (T cells, yellow). Prior to PD-1 blockade plus re-irradiation treatment, T cells tend to localize in the perivascular space, whereas after treatment, they seemed to migrate deeper into the tumor. For details, see the article by Iwamoto and colleagues on page 316 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
CCR Translations
Reviews
Update on Pediatric Surveillance Recommendations for PTEN Hamartoma Tumor Syndrome, DICER1-Related Tumor Predisposition, and Tuberous Sclerosis Complex
Kris Ann P. Schultz; Suzanne P. MacFarland; Melissa R. Perrino; Sarah G. Mitchell; Junne Kamihara; Alexander T. Nelson; Paige H.R. Mallinger; Jack J. Brzezinski; Kara N. Maxwell; Emma R. Woodward; Bailey Gallinger; Sun Young Kim; Mary-Louise C. Greer; Kami Wolfe Schneider; Sarah R. Scollon; Anirban Das; Jonathan D. Wasserman; Charis Eng; David Malkin; William D. Foulkes; Orli Michaeli; Andrew J. Bauer; Douglas R. Stewart
Clinical Trials: Targeted Therapy
Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma
Kevin J. Contrera; Renata Ferrarotto; Brandon Gunn; Shirley Y. Su; Merrill S. Kies; Bonnie S. Glisson; Adam S. Garden; Dianna Roberts; Curtis Habna; Camilla O. Hoff; Adel El-Naggar; Michelle D. Williams; Shaan M. Raza; Franco DeMonte; Melissa M. Chen; Mark S. Chambers; Ehab Y. Hanna
A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial
Francesca Sarno; Jair Tenorio; Sofia Perea; Laura Medina; Roberto Pazo-Cid; Ignacio Juez; Rocío Garcia-Carbonero; Jaime Feliu; Carmen Guillen-Ponce; Pedro P. Lopez-Casas; Carmen Guerra; Yolanda Duran; José Francisco López-Acosta; Carolina Alonso; Estrella Esquivel; Ana Dopazo; Dipikaa Akshinthala; Senthil K. Muthuswamy; Pablo Lapunzina; Bruno Bockorny; Manuel Hidalgo
Clinical Trials: Immunotherapy
A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
Sarina Piha-Paul; Shane A. Olwill; Erika Hamilton; Anthony Tolcher; Paula Pohlmann; Stephen V. Liu; Cornelia Wurzenberger; Laura-Carolin Hasenkamp; Eva-Maria Hansbauer; Rachna Shroff; Sara Hurvitz; Anuradha Krishnamurthy; Amita Patnaik; Noah Hahn; Raman Kumar; Manuela Duerr; Markus Zettl; Kayti Aviano; Louis Matis; Ingmar Bruns; Geoffrey Ku
A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer
Randy F. Sweis; Gurkamal S. Chatta; Rohit K. Jain; Helen Moon; Scott Edward Delacroix; Alana Fang; Leonard D’Amico; Angela Shaulov Kask; Martin A. Cheever; Steven Fling; Elad Sharon; Andreanne Lacroix; Judith C. Kaiser; Russell K. Pachynski; Evan Y. Yu
A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers
Young Kwang Chae; Lucy Corthell; Sandip Pravin Patel; Robert Edwards; Jennifer M. Scalici; Hye Sung Kim; Liam Il-Young Chung; Megan Othus; Christine M. McLeod; Helen X. Chen; Elad Sharon; Howard Streicher; Christopher W. Ryan; Charles D. Blanke; Razelle Kurzrock
Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma
Fabio M. Iwamoto; Shyam K. Tanguturi; Lakshmi Nayak; Tony J. Wang; Arati Desai; Robert A. Lustig; Stephen Bagley; Eric T. Wong; Lauren M. Hertan; Christine McCluskey; Julia Hayden; Alona Muzikansky; Shreya Nakhawa; Julia Japo; Connor C. Bossi; Maxime Meylan; Ye Tian; Graham L. Barlow; Paul Speliakos; Georges Ayoub; David M. Meredith; Keith L. Ligon; Daphne Haas-Kogan; Kun Huang; Kai W. Wucherpfennig; Patrick Y. Wen; David A. Reardon
Precision Medicine and Imaging
A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan
Yoshiaki Nakamura; Kristiyana Kaneva; Christine Lo; Daniel Neems; Jonathan E. Freaney; Hala Boulos; Seung Won Hyun; Farahnaz Islam; Jason Yamada-Hanff; Terri M. Driessen; Anne Sonnenschein; Dana F. DeSantis; Daisuke Kotani; Jun Watanabe; Masahito Kotaka; Saori Mishima; Hideaki Bando; Kentaro Yamazaki; Hiroya Taniguchi; Ichiro Takemasa; Takeshi Kato; Chithra Sangli; Robert Tell; Richard Blidner; Takayuki Yoshino; Kate Sasser; Eiji Oki; Halla Nimeiri
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Samuel Rosner; Sydney Connor; Khaled Sanber; Marianna Zahurak; Tianbei Zhang; Isha Gurumurthy; Zhen Zeng; Brad Presson; Dipika Singh; Roni Rayes; Lavanya Sivapalan; Gavin Pereira; Zhicheng Ji; Rohit Thummalapalli; Joshua E. Reuss; Stephen R. Broderick; David R. Jones; Julie S. Deutsch; Tricia R. Cottrell; Jamie E. Chaft; Jonathan Spicer; Janis Taube; Valsamo Anagnostou; Julie R. Brahmer; Drew M. Pardoll; Hongkai Ji; Patrick M. Forde; Kristen A. Marrone; Kellie N. Smith
Metabolic Tumor Volume Assessed by 18F FDG–PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates
Filippo G. Dall’Olio; Wael Zrafi; Veronique Roelants; Valentina Ambrosini; Aloyse Fourquet; Cristina Mitea; Francesco Passiglia; Matteo Bauckneht; Gerald Bonardel; Nicole Conci; Jose Carlos Benitez; Vincenzo Arena; Céline Namour; Marie Naigeon; Isabelle Monnet; Kristi Beshiri; Delphine Hoton; Safiye Dursun; François Xavier Danlos; Giulia Argalia; Mihaela Aldea; Guido Rovera; Lisa Derosa; Valerio Iebba; Hester A. Gietema; Valerie Gounant; Valérie Lacroix; Jordi Remon; Daniel Gautheret; Nathalie Chaput; Bastien Job; Patricia L. Kannouche; Monica Velasco-Nuño; Laurence Zitvogel; Eugenia Cella; José Reinaldo Chícharo de Freitas; Damien Vasseur; Mohamed Aymen Bettaieb; Marco Tagliamento; Lizza Hendriks; Antoine Italiano; David Planchard; Aurelien Marabelle; Fabrice Barlesi; Silvia Novello; Desiree De Andreis; Frank Aboubakar Nana; Andrea Ardizzoni; Gerard Zalcman; Camilo Garcia; Benjamin Besse
Analysis of Shared Variants between Cancer Biospecimens
Michael B. Foote; James Robert White; Walid K. Chatila; Guillem Argilés; Steve Lu; Benoit Rousseau; Oliver Artz; Paul Johannet; Henry Walch; Mitesh Patel; Michelle F. Lamendola-Essel; David Casadevall; Somer Abdelfattah; Shrey Patel; Rona Yaeger; Andrea Cercek; Clara Montagut; Michael Berger; Nikolaus Schultz; Luis A. Diaz, Jr
Translational Cancer Mechanisms and Therapy
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer
Timothy P. DiPeri; Kurt W. Evans; Stephen Scott; Xiaofeng Zheng; Kaushik Varadarajan; Lawrence N. Kwong; Michael Kahle; Hop S. Tran Cao; Ching-Wei Tzeng; Thuy Vu; Sunhee Kim; Fei Su; Maria Gabriela Raso; Yasmeen Rizvi; Ming Zhao; Huamin Wang; Sunyoung S. Lee; Timothy A. Yap; Jordi Rodon; Milind Javle; Funda Meric-Bernstam
Hormone Receptor–Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers
Alejandro Rios-Hoyo; Kaitlyn Xiong; Jiawei Dai; Christina Yau; Michal Marczyk; Rolando Garcia-Milian; Denise M. Wolf; Laura A. Huppert; Rita Nanda; Gillian L. Hirst; Erin F. Cobain; Laura J. van ’t Veer; Laura J. Esserman; Lajos Pusztai
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.